Morbus Parkinson

Aus PlusPedia
Wechseln zu: Navigation, Suche
Klassifikation nach ICD-10
G 20 Morbus Parkinson
ICD-10-GM Version 2020
Entstehender Artikel
Siehe auch
Freie Übersichtsartikel

[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79] [80]

Wichtige Übersichtsartikel [81]
Medline Suchterm/ Synonyme
Was ist das
Struktur
Physiologie
Knockout
Transgen
Mutation
Polymorphismus
Genexpression
Inhibitoren
Agonisten

1 Bibliographie

  1. ↑ Parkinson's disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care 14(2 Suppl):S59-69 (2008) PMID 18402509
  2. ↑ Parkinson's disease--Part 2: Treatment of motor symptoms. Am J Manag Care 14(2 Suppl):S49-58 (2008) PMID 18402508
  3. ↑ Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14(2 Suppl):S40-8 (2008) PMID 18402507
  4. ↑ Update on Parkinson disease. Ann Intern Med 138(8):651-8 (2003) PMID 12693888
  5. ↑ A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64(5):485-91 (2008) PMID 19067353
  6. ↑ Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch Neurol 65(12):1577-81 (2008) PMID 19064744
  7. ↑ Phenotypic commonalities in familial and sporadic Parkinson disease. Arch Neurol 63(4):579-83 (2006) PMID 16606772
  8. ↑ Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63(3):328-34 (2006) PMID 16533959
  9. ↑ Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol 62(9):1343-4 (2005) PMID 16157740
  10. ↑ Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? Arch Neurol 62(4):533-6 (2005) PMID 15824249
  11. ↑ Molecular pathogenesis of Parkinson disease. Arch Neurol 62(3):353-7 (2005) PMID 15767499
  12. ↑ Initial Parkinson disease therapy: levodopa, dopamine agonists, or both? Arch Neurol 61(12):1972-3 (2004) PMID 15596625
  13. ↑ Dopamine agonists modify the course of Parkinson disease. Arch Neurol 61(12):1969-71 (2004) PMID 15596624
  14. ↑ Initial treatment of Parkinson disease: levodopa or dopamine agonists. Arch Neurol 61(12):1966-9 (2004) PMID 15596623
  15. ↑ Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol 58(12):1970-2 (2001) PMID 11735770
  16. ↑ Subthalamic deep brain stimulation: neurobehavioral concerns. Arch Neurol 58(8):1205-6 (2001) PMID 11493159
  17. ↑ Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol 57(8):1118-25 (2000) PMID 10927791
  18. ↑ Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Arch Neurol 56(9):1064-9 (1999) PMID 10488806
  19. ↑ New and emerging therapies for Parkinson disease. Arch Neurol 56(7):785-90 (1999) PMID 10404979
  20. ↑ Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56(5):529-35 (1999) PMID 10328247
  21. ↑ Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33-9 (1999) PMID 9923759
  22. ↑ Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy 4(3):372-4 (2008) PMID 18216494
  23. ↑ The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131(Pt 8):1969-78 (2008) PMID 18187492
  24. ↑ Biomarkers and Parkinson's disease. Brain 127(Pt 8):1693-705 (2004) PMID 15215212
  25. ↑ The pedunculopontine nucleus and Parkinson's disease. Brain 123 ( Pt 9)():1767-83 (2000) PMID 10960043
  26. ↑ Neuropsychological outcome following unilateral pallidotomy. Brain 122 ( Pt 12)():2209-20 (1999) PMID 10581217
  27. ↑ Unilateral pallidotomy for advanced Parkinson's disease. Brain 122 ( Pt 3)():381-2 (1999) PMID 10094248
  28. ↑ CRYOTHALAMECTOMY FOR PARKINSON'S DISEASE. Calif Med 101():248-52 (1964) PMID 14201235
  29. ↑ L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 101(13):59-68 (1969) PMID 4903690
  30. ↑ Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ 14(7):1261-6 (2007) PMID 17464321
  31. ↑ Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 5(10):832-7 (1998) PMID 10203692
  32. ↑ How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 5(7):681-5 (2004) PMID 15229644
  33. ↑ Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? Exp Biol Med (Maywood) 233(8):941-51 (2008) PMID 18535172
  34. ↑ Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J 275(23):5767-73 (2008) PMID 19021754
  35. ↑ Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 14(18):2749-55 (2005) PMID 16126732
  36. ↑ Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 13 Spec No 1():R127-33 (2004) PMID 14976155
  37. ↑ Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11(20):2395-407 (2002) PMID 12351575
  38. ↑ The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet 8(10):1901-5 (1999) PMID 10469843
  39. ↑ Parkinson's disease: from etiology to treatment. Intern Med 34(11):1045-54 (1995) PMID 8774962
  40. ↑ Subthalamic stimulation for Parkinson's disease. Isr Med Assoc J 7(7):458-63 (2005) PMID 16011063
  41. ↑ Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116(7):1744-54 (2006) PMID 16823471
  42. ↑ STN stimulation and neuroprotection in Parkinson's disease--when beautiful theories meet ugly facts. J Neurol Neurosurg Psychiatry 76(9):1186-7 (2005) PMID 16107346
  43. ↑ Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry 76(8):1058-63 (2005) PMID 16024878
  44. ↑ Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 76(7):903-4 (2005) PMID 15965192
  45. ↑ Beyond the holy grail of motor symptoms: deep brain stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 76(6):759-60 (2005) PMID 15897490
  46. ↑ Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement. J Neurol Neurosurg Psychiatry 76(3):409-14 (2005) PMID 15716537
  47. ↑ Early pathological changes in the parkinsonian brain. J Neurol Neurosurg Psychiatry 75(3):352 (2004) PMID 14966144
  48. ↑ Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 68(6):685-9 (2000) PMID 10811688
  49. ↑ Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry 62(1):2-8 (1997) PMID 9010390
  50. ↑ How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 61(1):4-16 (1996) PMID 8676157
  51. ↑ Parkinson's disease. J Neurol Neurosurg Psychiatry 57(6):672-81 (1994) PMID 7755681
  52. ↑ The on-off phenomenon. J Neurol Neurosurg Psychiatry Suppl():29-37 (1989) PMID 2666577
  53. ↑ Clues to the mechanism underlying dopamine cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry Suppl():22-8 (1989) PMID 2666576
  54. ↑ Is "Parkinson's disease" one disease? J Neurol Neurosurg Psychiatry Suppl():18-21 (1989) PMID 2666575
  55. ↑ Current theories on the cause of Parkinson's disease. J Neurol Neurosurg Psychiatry Suppl():13-7 (1989) PMID 2666574
  56. ↑ Speech disorders of Parkinsonism: a review. J Neurol Neurosurg Psychiatry 44(9):751-8 (1981) PMID 7031185
  57. ↑ Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 54(6):414-8 (2001) PMID 11724917
  58. ↑ The aetiology of idiopathic Parkinson's disease. Mol Pathol 54(6):369-80 (2001) PMID 11724911
  59. ↑ Neuroimaging in Parkinson's disease. NeuroRx 1(2):243-54 (2004) PMID 15717025
  60. ↑ Genetics of Parkinson disease. NeuroRx 1(2):235-42 (2004) PMID 15717024
  61. ↑ Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1(1):139-54 (2004) PMID 15717014
  62. ↑ Molecules that cause or prevent Parkinson's disease. PLoS Biol 2(11):e401 (2004) PMID 15547643
  63. ↑ Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 80(946):452-8 (2004) PMID 15299154
  64. ↑ Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J 79(936):561-5 (2003) PMID 14612597
  65. ↑ Pharmacological treatment of Parkinson's disease. Postgrad Med J 76(900):602-10 (2000) PMID 11009573
  66. ↑ Parkinson's disease. Postgrad Med J 73(859):257-64 (1997) PMID 9196696
  67. ↑ Parkinson's disease. Postgrad Med J 68(801):538-43 (1992) PMID 1437950
  68. ↑ Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 64(751):345-51 (1988) PMID 3059338
  69. ↑ The treatment of Parkinson's disease. Postgrad Med J 53(626):729-31 (1977) PMID 343079
  70. ↑ Symptomatic Parkinsonism. Postgrad Med J 53(626):726-8 (1977) PMID 343078
  71. ↑ Physiology of abnormal movements. Postgrad Med J 53(626):713-8 (1977) PMID 343077
  72. ↑ The biochemistry of the basal ganglia and Parkinson's disease. Postgrad Med J 53(626):719-25 (1977) PMID 24209
  73. ↑ Augmenting the action of levodopa. Postgrad Med J 48(565):653-6 (1972) PMID 4568331
  74. ↑ Current concepts of Parkinsonism. Postgrad Med J 47(554):794-9 (1971) PMID 4945017
  75. ↑ Parkinson's disease. Diagnosis and treatment. West J Med 165(4):234-40 (1996) PMID 8987437
  76. ↑ Treatment of Parkinson's disease. West J Med 161(3):303-8 (1994) PMID 7975571
  77. ↑ Parkinson's disease and levodopa. A five-year follow-up and review. West J Med 121(3):188-206 (1974) PMID 4606887
  78. ↑ Are ubiquitination pathways central to Parkinson's disease? Cell 114(1):1-8 (2003) PMID 12859888
  79. ↑ alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565(1-3):1-5 (2004) PMID 15135042
  80. ↑ Laura B. Zahodne, Hubert H. Fernandez, A Review of the Pathophysiology and Treatment of Psychosis in Parkinson’s Disease Drugs Aging. 2008 ; 25(8): 665–682.
  81. ↑ Treatment of Psychosis and Dementia in Parkinson’s Disease

2 Andere Lexika

Abgerufen von „http://de.pluspedia.org/w/index.php?title=Morbus_Parkinson&oldid=473158“

Diesen Artikel melden!
Verletzt dieser Artikel deine Urheber- oder Persönlichkeitsrechte?
Hast du einen Löschwunsch oder ein anderes Anliegen? Dann nutze bitte unser Kontaktformular

PlusPedia Impressum
Diese Seite mit Freunden teilen:
Mr Wong Digg Delicious Yiggit wikio Twitter
Facebook


Bitte Beachte:
Sämtliche Aussagen auf dieser Seite sind ohne Gewähr.
Für die Richtigkeit der Aussagen übernimmt die Betreiberin keine Verantwortung.
Nach Kenntnissnahme von Fehlern und Rechtsverstößens ist die Betreiberin selbstverständlich bereit,
diese zu beheben.

Verantwortlich für jede einzelne Aussage ist der jeweilige Erstautor dieser Aussage.
Mit dem Ergänzen und Weiterschreiben eines Artikels durch einen anderen Autor
werden die vorhergehenden Aussagen und Inhalte nicht zu eigenen.
Die Weiternutzung und Glaubhaftigkeit der Inhalte ist selbst gegenzurecherchieren.


Typo3 Besucherzähler - Seitwert blog counter
java hosting vpn norway